HOUSE FDA REFORM BILL'S "SCOPE OF REVIEW," THIRD-PARTY PROVISIONS COULD BE CHANGED BEFORE SEPT. 25 COMMITTEE MARK-UP; HEALTH SUBCMTE. CLEARS BILL SEPT. 17
This article was originally published in The Gray Sheet
Executive SummaryProvisions in the House FDA device reform bill (HR 1710) limiting FDA 510(k) review authority to claims made in labeling and codifying a third-party review program could be modified to address Democratic concerns before Commerce Committee mark-up of the bill on Sept. 25.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.